bullish

Akeso Biopharma Inc (9926 HK) - Something Beautiful Is Happening

186 Views11 Sep 2024 08:55
​AK112's HARMONi-2 results show promise, but FDA approval depends on OS. Summit is actually a better investment than Akeso. Investors bet Summit to be acquired, but anti-monopoly issue poses challenge
What is covered in the Full Insight:
  • Introduction to AK112's HARMONi-2 Results
  • Comparison with Pembrolizumab
  • Global Rights and Market Potential
  • Challenges and FDA Approval
  • Potential Acquisition of Summit
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x